Dialysis firm FMC's earnings miss market view, hit by severe flu season in US

Dialysis firm Fresenius Medical Care (FMC) reported Q2 adjusted operating income of €476 million, missing the €492 million consensus, primarily due to a severe U.S. flu season that increased patient mortality and missed treatments, resulting in flat U.S. same-market treatment growth. Shares declined approximately 3% on the news. Despite the earnings miss, revenue grew 5% to €4.79 billion, slightly exceeding expectations, benefiting from transformation program savings. The company affirmed its full-year guidance, anticipating significant operational and financial improvements in the second half, and will initiate a €1 billion share buyback program in August, signaling confidence despite the Q2 headwinds.

Analysis

Fresenius Medical Care (FMC) reported mixed second-quarter results, characterized by an earnings miss offset by strong forward-looking signals from management. The company's adjusted operating income of €476 million, despite a 9% year-over-year growth, fell short of the €492 million analyst consensus, a miss attributed to a severe U.S. flu season that increased patient mortality and missed treatments. This headwind directly resulted in flat U.S. same-market treatment growth, a critical operational metric that now requires significant second-half acceleration to meet the full-year guidance of over 0.5% growth. Despite these challenges, which prompted an approximate 3% decline in the share price, the company posted a 5% constant currency revenue increase to €4.79 billion, slightly beating expectations, supported by €58 million in savings from its FME25 transformation program. Critically, management reaffirmed its full-year guidance and announced the initiation of a €1 billion share buyback in August, signaling strong confidence in future operational improvements and underlying business health despite the quarter's external pressures.

Key Decisions for Investors

• Investors should weigh the temporary nature of the flu-related headwinds against management's confidence, reflected in the confirmed full-year guidance and a substantial €1 billion share buyback program.
• The approximate 3% share price decline following the earnings miss could present a buying opportunity for those who believe the patient mortality issue is transient and that operational improvements will materialize in the second half as guided.
• Closely monitor U.S. same-market treatment growth in H2, as the company's ability to meet its full-year target of over 0.5% growth is now a key validation point for the investment thesis.